News $40bn Teva generic deal awaits antitrust approval Acquisition of Allergan's generics business ready.
News Impax buys Teva and Allergan generics for $586 million Teva must sell some assets before buying Allergan's generics business.
News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
Articles Teva: looking for innovation and growth in ‘space between’ b... Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
